Format

Send to

Choose Destination
JAMA Intern Med. 2019 Feb 1;179(2):213-223. doi: 10.1001/jamainternmed.2018.5849.

Association of Corticosteroid Treatment With Outcomes in Adult Patients With Sepsis: A Systematic Review and Meta-analysis.

Author information

1
West China Hospital, Sichuan University, Chengdu, Sichuan, China.
2
Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
3
Chinese University of Hong Kong, Shenzhen, Guangdong, China.
4
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
5
Longquanyi Hospital, Chengdu, Sichuan, China.
6
Southwest Hospital, Army Medical University, Chongqing, China.
7
Sichuan University Library, Chengdu, Sichuan, China.

Abstract

Importance:

Although corticosteroids are widely used for adults with sepsis, both the overall benefit and potential risks remain unclear.

Objective:

To conduct a systematic review and meta-analysis of the efficacy and safety of corticosteroids in patients with sepsis.

Data Sources and Study Selection:

MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception until March 20, 2018, and updated on August 10, 2018. The terms corticosteroids, sepsis, septic shock, hydrocortisone, controlled trials, and randomized controlled trial were searched alone or in combination. Randomized clinical trials (RCTs) were included that compared administration of corticosteroids with placebo or standard supportive care in adults with sepsis.

Data Extraction and Synthesis:

Meta-analyses were conducted using a random-effects model to calculate risk ratios (RRs) and mean differences (MDs) with corresponding 95% CIs. Two independent reviewers completed citation screening, data abstraction, and risk assessment.

Main Outcomes and Measures:

Twenty-eight-day mortality.

Results:

This meta-analysis included 37 RCTs (N = 9564 patients). Eleven trials were rated as low risk of bias. Corticosteroid use was associated with reduced 28-day mortality (RR, 0.90; 95% CI, 0.82-0.98; I2 = 27%) and intensive care unit (ICU) mortality (RR, 0.85; 95% CI, 0.77-0.94; I2 = 0%) and in-hospital mortality (RR, 0.88; 95% CI, 0.79-0.99; I2 = 38%). Corticosteroids were significantly associated with increased shock reversal at day 7 (MD, 1.95; 95% CI, 0.80-3.11) and vasopressor-free days (MD, 1.95; 95% CI, 0.80-3.11) and with ICU length of stay (MD, -1.16; 95% CI, -2.12 to -0.20), the sequential organ failure assessment score at day 7 (MD, -1.38; 95% CI, -1.87 to -0.89), and time to resolution of shock (MD, -1.35; 95% CI, -1.78 to -0.91). However, corticosteroid use was associated with increased risk of hyperglycemia (RR, 1.19; 95% CI, 1.08-1.30) and hypernatremia (RR, 1.57; 95% CI, 1.24-1.99).

Conclusions and Relevance:

The findings suggest that administration of corticosteroids is associated with reduced 28-day mortality compared with placebo use or standard supportive care. More research is needed to associate personalized medicine with the corticosteroid treatment to select suitable patients who are more likely to show a benefit.

PMID:
30575845
PMCID:
PMC6439648
[Available on 2019-12-21]
DOI:
10.1001/jamainternmed.2018.5849

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center